{"id":35090,"date":"2025-06-12T14:16:57","date_gmt":"2025-06-12T06:16:57","guid":{"rendered":"https:\/\/flcube.com\/?p=35090"},"modified":"2025-06-12T14:16:58","modified_gmt":"2025-06-12T06:16:58","slug":"daiichi-sankyo-launches-phase-i-trial-for-enhertu-subcutaneous-formulation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35090","title":{"rendered":"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation"},"content":{"rendered":"\n

Japan-based Daiichi Sankyo (TYO: 4568<\/a>) has registered a Phase I clinical trial on ClinicalTrials.gov for the subcutaneous formulation of Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody drug conjugate (ADC), in metastatic solid tumors. The study is expected to enroll 76 patients with advanced solid malignancies.<\/p>\n\n\n\n

Licensing Agreement with Alreogen<\/strong>
This development follows Daiichi Sankyo’s November 2024 licensing agreement with Korean biotech Alreogen for its proprietary Hybrozyme technology. Hybrozyme enables the development of subcutaneous trastuzumab deruxtecan, enhancing patient convenience through a more efficient administration route.<\/p>\n\n\n\n

Financial Terms<\/strong>
Under the agreement, Daiichi Sankyo paid an upfront fee of USD 20 million and is committed to potential milestone payments totaling up to USD 280 million. The total deal value reaches USD 300 million, reflecting the significant potential of the subcutaneous formulation in expanding Enhertu’s therapeutic applications.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for…<\/p>\n","protected":false},"author":1,"featured_media":35092,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,62,194,978],"class_list":["post-35090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-daiichi-sankyo","tag-tyo-4568"],"yoast_head":"\nDaiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for the subcutaneous formulation of Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody drug conjugate (ADC), in metastatic solid tumors. The study is expected to enroll 76 patients with advanced solid malignancies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35090\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation\" \/>\n<meta property=\"og:description\" content=\"Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for the subcutaneous formulation of Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody drug conjugate (ADC), in metastatic solid tumors. The study is expected to enroll 76 patients with advanced solid malignancies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35090\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-12T06:16:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-12T06:16:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation\",\"datePublished\":\"2025-06-12T06:16:57+00:00\",\"dateModified\":\"2025-06-12T06:16:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090\"},\"wordCount\":144,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1203.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"Daiichi Sankyo\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35090#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35090\",\"name\":\"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1203.webp\",\"datePublished\":\"2025-06-12T06:16:57+00:00\",\"dateModified\":\"2025-06-12T06:16:58+00:00\",\"description\":\"Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for the subcutaneous formulation of Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody drug conjugate (ADC), in metastatic solid tumors. The study is expected to enroll 76 patients with advanced solid malignancies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35090\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35090#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation - Insight, China's Pharmaceutical Industry","description":"Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for the subcutaneous formulation of Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody drug conjugate (ADC), in metastatic solid tumors. The study is expected to enroll 76 patients with advanced solid malignancies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35090","og_locale":"en_US","og_type":"article","og_title":"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation","og_description":"Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for the subcutaneous formulation of Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody drug conjugate (ADC), in metastatic solid tumors. The study is expected to enroll 76 patients with advanced solid malignancies.","og_url":"https:\/\/flcube.com\/?p=35090","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-12T06:16:57+00:00","article_modified_time":"2025-06-12T06:16:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35090#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35090"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation","datePublished":"2025-06-12T06:16:57+00:00","dateModified":"2025-06-12T06:16:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35090"},"wordCount":144,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35090#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1203.webp","keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","Daiichi Sankyo","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35090#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35090","url":"https:\/\/flcube.com\/?p=35090","name":"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35090#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35090#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1203.webp","datePublished":"2025-06-12T06:16:57+00:00","dateModified":"2025-06-12T06:16:58+00:00","description":"Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for the subcutaneous formulation of Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody drug conjugate (ADC), in metastatic solid tumors. The study is expected to enroll 76 patients with advanced solid malignancies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35090#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35090"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35090#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1203.webp","width":1080,"height":608,"caption":"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35090#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35090"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35090\/revisions"}],"predecessor-version":[{"id":35093,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35090\/revisions\/35093"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35092"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}